- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:58 | Everlywell rolls out Clairity AI for breast cancer in US | ||
| 12:59 | New diabetes and obesity studies making waves at EASD | ||
| 11:58 | UK puts £80m behind dementia diagnosis push | ||
| 10:58 | Space pharma Varda raises $251m, and other financings | ||
| 09:58 | pharmaphorum renews strategic media partnership with Frontiers Health 2026 | ||
| Do | NICE backs Sobi's Tryngolza for rare disease FCS | ||
| Do | Bayer names Christoph Koenen as its new CMO | ||
| Do | Sanofi forges new $8bn pact with Regeneron | ||
| Do | GLOBE model finalised, with narrowed scope and fewer savings | ||
| Do | New Lilly combo tops tirzepatide for weight loss in diabetes | ||
| Mi | Apogee buy delivers eczema trial win for AbbVie | ||
| Mi | Two men charged with infiltrating fake Ozempic into US | ||
| Mi | Lilly fleshes out triple G data in diabetes and obesity | ||
| Mi | PhRMA hires ex-House Majority Leader Eric Cantor as its CEO | ||
| Di | uniQure falls on long-term Huntington's gene therapy data | ||
| Di | Novo turns to Hengrui for another oral obesity drug | ||
| Di | Mirum puts Hepcludex in its sights with hep D readout | ||
| Di | AZ takes stake in Summit Therapeutics in $2bn deal | ||
| Di | FDA clears first drug for MCT8 deficiency | ||
| Mo | MSD takes a $400m bite of SciBrunch's KRAS drug | ||
| Mo | Roche culls myostatin candidate from obesity pipeline | ||
| Mo | Test could end uncertainty in inherited muscle diseases | ||
| Mo | AbbVie's Cerevel takeover delivers Parkinson's approval | ||
| Mo | MSD, Daiichi pull filing for lung cancer candidate I-DXd | ||
| Mo | FDA approves Mirum's oral drug for rare disease FOP |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.